Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_24_2566 - Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated With Chemoradiotherapy

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated With Chemoradiotherapy
E. Muraro1, E. Vaccher2, C. Furlan3,4, E. Fratta1, D. A. Fae'1, D. Martorelli1, J. Polesel5, G. Fanetti4, E. Farina4, F. Navarria4, E. Comaro1, V. Lupato6, V. Giacomarra6, S. Sulfaro7, L. Barzan8, G. Grando6, R. Dolcetti9, A. Steffan1, V. Canzonieri10, and G. Franchin4; 1Immunopathology and Biomarker Unit, Department of Translational Research, Centro di Riferimento Oncologico, Aviano, Italy, 2Infectious Disease and Tumors Unit, Department of Clinical Oncology, Centro di Riferimento Oncologico, Aviano, Italy, 3Division of Radiation Oncology, San Martino Hospital, Belluno, Italy, 4Department of Radiation Oncology, Centro di Riferimento Oncologico, Aviano, Italy, 5Unit of Cancer Epidemiology, Centro di Riferimento Oncologico, Aviano, Italy, 6Unit of Otolaryngology, S. Maria degli Angeli General Hospital, Pordenone, Italy, 7Unit of Pathology, S. Maria degli Angeli General Hospital, Pordenone, Italy, 8Department of Surgery, Centro di Riferimento Oncologico, Aviano, Italy, 9University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, 10Unit of Pathology, Centro di Riferimento Oncologico, Aviano, Italy

Purpose/Objective(s): EBV-associated UNPC is characterized by an abundant immune infiltrate, which may have a prognostic relevance, considering EBV-specific immune response and microenvironmental immunesuppression. Our primary aim was to retrospectively assess the significance of immunesuppression in the UNPC microenvironment as prognostic biomarker of treatment failure in a non-endemic area population. As secondary aim we investigated the immunomodulating effects of chemoradiotherapy (CRT) monitoring the variation of EBV-specific immunity before and after treatment.

Materials/Methods: We reviewed 63 consecutive patients (pts) with EBV-associated stage II-IVB UNPC undergoing radical CRT. Our policy was of administering concurrent CRT in pts with stage II disease, and sequential therapy in pts with advanced stages. The number of relapsed pts was 11 (cases), while 52 pts (controls) were free from treatment failure at a minimum follow-up of 2 years. DNA and RNA were extracted from tumor (T) and adjacent normal mucosa (M) frozen biopsies at diagnosis. We verified the expression of EBV-derived Barf1 gene in T versus M samples. We investigated the expression of the immune-related genes PD-L1, CD8, FoxP3 and IFN-g in T and M tissues by quantitative RealTime PCR, and their methylation status through quantitative methylation specific PCR.

Results: Quantitative RT-PCR analyses showed significantly higher expression levels of several immune-related genes (i.e. BARF1, CD8, IFN-g, IDO, PD-L1, and PD-1) in UNPC samples respect to healthy tissues. Interestingly, CD8 expression was significantly reduced in both tumor and healthy tissues in UNPC patients who relapsed within two years (P<0.001). Similarly, quantitative methylation-specific PCR analyses identified a hypomethylated FOXP3 intron 1 exclusively in relapsed UNPC patients. Finally, we quantified the amount of EBV- and BARF1-specific T-cells in the peripheral blood of 14 patients (7 relapses) through IFN-g ELISPOT assay, and observed a significant decrease after CRT only in relapsing patients.

Conclusion: Altogether, our data suggest that a high level of immunosuppression (low CD8, hypomethylated FoxP3) in UNPC microenvironment may predict treatment failure and early identify those patients who could benefit from the addition of an immunotherapy improving first line CRT.

Author Disclosure: E. Muraro: None. E. Vaccher: None. D. Martorelli: None. F. Navarria: None.

Giuseppe Fanetti, MD

Biography:
Giuseppe Fanetti, Radiation Oncologist, MD, IRCCS Centro di Riferimento Oncologico (CRO) National Cancer Institute, Aviano, Italy
I am an Italian Medical Doctor with specialization in Radiation Oncology. I'm 39 years old and I graduated at University of Bari with a thesis in the field of Hematology in 2009. After my graduation, I moved to Milan were I worked at the Department of Medical Oncology focusing on chemotherapy and target therapies for various neoplasm. In that period, my fields of interest were breast cancer and gastrointestinal malignancies. In 2013 I started my residency in Radiation Oncology at the European Institute of Milan where I gained particular experience in breast, prostate, lung and head and neck cancers. During the last years of this training, I had the possibility to visit the Division of Radiotherapy of the University Medical Center (UMC) of Utrecht and to work at the Department of Radiation Oncology of IRCCS Centro di Riferimento Oncologico (CRO) National Cancer Institute of Aviano to increase my skills in Head and Neck cancers and systemic radioisotope therapy for Thyroid cancer and bone metastases. After my residency period, I continued working at CRO of Aviano keeping the interest in Head and Neck tumors.

Presentation(s):

Send Email for Giuseppe Fanetti


Assets

MO_24_2566 - Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated With Chemoradiotherapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Prognostic Significance of Immune Microenvironmental Factors in Undifferentiated Nasopharyngeal Carcinoma Patients Treated With Chemoradiotherapy